Journal article

DEVELOPMENT OF A CELL-BASED TREATMENT FOR LONG-TERM NEUROTROPHIN EXPRESSION AND SPIRAL GANGLION NEURON SURVIVAL

MP Zanin, M Hellstroem, RK Shepherd, AR Harvey, LN Gillespie

NEUROSCIENCE | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2014

Abstract

Spiral ganglion neurons (SGNs), the target cells of the cochlear implant, undergo gradual degeneration following loss of the sensory epithelium in deafness. The preservation of a viable population of SGNs in deafness can be achieved in animal models with exogenous application of neurotrophins such as brain-derived neurotrophic factor (BDNF) and neurotrophin-3. For translation into clinical application, a suitable delivery strategy that provides ongoing neurotrophic support and promotes long-term SGN survival is required. Cell-based neurotrophin treatment has the potential to meet the specific requirements for clinical application, and we have previously reported that Schwann cells geneticall..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Health and Medical Research Council of Australia


Funding Acknowledgements

We thank Rebecca Argent for technical assistance, and Professor Johnson Mak for access to the AMAXA Nucleofector II. This work was supported by the National Health and Medical Research Council of Australia (APP526901) and the Garnett Passe and Rodney Williams Memorial Foundation. The Bionics Institute acknowledges the support it receives from the Victorian Government through its Operational Infrastructure Support Program. The funding bodies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.